Excellent
Fully Aligned
Patient Risk:
Low
Summary
The evaluated warning-content summary (thyroid C-cell tumor risk) is directly supported by the provided Zepbound prescribing information sections, including the boxed warning topic (5.1), contraindications (4), carcinogenesis evidence (13.1), and patient counseling (17).
Category Scores
Accurate Statements
ZEPBOUND prescribing information states that tirzepatide caused a dose- and treatment-duration-dependent increase in thyroid C-cell tumors in rats and that human relevance is unknown.
5.1; 13.1
ZEPBOUND is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with MEN 2.
4; 5.1
Patients should be counseled regarding potential risk for MTC and symptoms of thyroid tumors.
5.1; 17
Routine monitoring with serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC.
5.1
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No unsupported or contradictory safety statements were made for the thyroid C-cell tumor warning content; the summary matches the label’s risk description, contraindication basis, and counseling/monitoring uncertainty language.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement